

Customer No. 22,852
Attorney Docket No. 04853.0087

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Hidemi SAITO et al.)
) Group Art Unit:
Serial No.: Not Yet Assigned)
) Examiner:
Filed: January 4, 2002)
)
For: THERAPEUTIC AGENT FOR)
DRUG-RESISTANT)
HYPERCALCEMIA)

National Phase of International Application No. PCT/JP00/04523

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO-1449 and cited in the international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed with the above-referenced application.

In lieu of a statement of relevance or the translation of the non-English documents, enclosed is an English-language international search report from the Japanese Patent Office in the PCT international application, from which this national

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202-408-4000
Fax 202-408-4400
www.finnegan.com

phase U.S. application is derived, citing these documents and setting forth the relevance thereof.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 4, 2002

By: 
Ernest F. Chapman
Reg. No. 25,961

Enclosures
EFC/FPD/gah

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

10/019785
 13 Rec'd PCT/PTO 0 4 JAN 2002
 OMB No. 0651-0011

Atty. Docket No.	04853.0087	Serial No.	
Applicant	Hidemi SAITO et al.		
Filing Date	January 4, 2002	Group:	

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,849,695	12/15/1998	Cohen et al.			

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	4-228089	08/18/1992	Japan			Abstract
	2-207099	08/16/1990	Japan			Abstract
	7-165790	06/27/1995	Japan			Abstract
	Q 962 467	12/08/1999	Europe			
	WO 92/17602	10/15/1992	PCT			
	WO 96/03437	02/08/1996	PCT			
	WO 92/00753	01/23/1992	PCT			
	0 449 405	10/02/1991	Europe			
	WO 96/33735	10/31/1996	PCT			
	1 004 313	05/31/2000	Europe			
	1 090 643	04/11/2001	Europe			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Ikeda et al.; "MOLECULAR BIOLOGY OF PARATHYROID HORMONE-RELATED PEPTIDE"; Nihon Rinshou 53(4), pages 37-45, (1995)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce